Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study
Type 2 diabetes (T2D) represents one of the major health issues of this century. Despite the availability of an increasing number of anti-hyperglycemic drugs, a significant proportion of patients are inadequately controlled, thus highlighting the need for novel biomarkers to guide treatment selectio...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/17/9454 |
| _version_ | 1797521339598241792 |
|---|---|
| author | Caterina Formichi Daniela Fignani Laura Nigi Giuseppina Emanuela Grieco Noemi Brusco Giada Licata Claudia Sabato Elisabetta Ferretti Guido Sebastiani Francesco Dotta |
| author_facet | Caterina Formichi Daniela Fignani Laura Nigi Giuseppina Emanuela Grieco Noemi Brusco Giada Licata Claudia Sabato Elisabetta Ferretti Guido Sebastiani Francesco Dotta |
| author_sort | Caterina Formichi |
| collection | DOAJ |
| description | Type 2 diabetes (T2D) represents one of the major health issues of this century. Despite the availability of an increasing number of anti-hyperglycemic drugs, a significant proportion of patients are inadequately controlled, thus highlighting the need for novel biomarkers to guide treatment selection. MicroRNAs (miRNAs) are small non-coding RNAs, proposed as useful diagnostic/prognostic markers. The aim of our study was to identify a miRNA signature occurring in responders to glucagon-like peptide 1 receptor agonists (GLP1-RA) therapy. We investigated the expression profile of eight T2D-associated circulating miRNAs in 26 prospectively evaluated diabetic patients in whom GLP1-RA was added to metformin. As expected, GLP1-RA treatment induced significant reductions of HbA1c and body weight, both after 6 and 12 months of therapy. Of note, baseline expression levels of the selected miRNAs revealed two distinct patient clusters: “high expressing” and “low expressing”. Interestingly, a significantly higher percentage of patients in the high expression group reached the glycemic target after 12 months of treatment. Our findings suggest that the evaluation of miRNA expression could be used to predict the likelihood of an early treatment response to GLP1-RA and to select patients in whom to start such treatment, paving the way to a personalized medicine approach. |
| first_indexed | 2024-03-10T08:11:13Z |
| format | Article |
| id | doaj.art-de446666154749fa97af16139f783eb8 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T08:11:13Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-de446666154749fa97af16139f783eb82023-11-22T10:43:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-08-012217945410.3390/ijms22179454Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot StudyCaterina Formichi0Daniela Fignani1Laura Nigi2Giuseppina Emanuela Grieco3Noemi Brusco4Giada Licata5Claudia Sabato6Elisabetta Ferretti7Guido Sebastiani8Francesco Dotta9Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyDiabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyDiabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyDiabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyDiabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyDiabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, ItalyDiabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyDiabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, ItalyType 2 diabetes (T2D) represents one of the major health issues of this century. Despite the availability of an increasing number of anti-hyperglycemic drugs, a significant proportion of patients are inadequately controlled, thus highlighting the need for novel biomarkers to guide treatment selection. MicroRNAs (miRNAs) are small non-coding RNAs, proposed as useful diagnostic/prognostic markers. The aim of our study was to identify a miRNA signature occurring in responders to glucagon-like peptide 1 receptor agonists (GLP1-RA) therapy. We investigated the expression profile of eight T2D-associated circulating miRNAs in 26 prospectively evaluated diabetic patients in whom GLP1-RA was added to metformin. As expected, GLP1-RA treatment induced significant reductions of HbA1c and body weight, both after 6 and 12 months of therapy. Of note, baseline expression levels of the selected miRNAs revealed two distinct patient clusters: “high expressing” and “low expressing”. Interestingly, a significantly higher percentage of patients in the high expression group reached the glycemic target after 12 months of treatment. Our findings suggest that the evaluation of miRNA expression could be used to predict the likelihood of an early treatment response to GLP1-RA and to select patients in whom to start such treatment, paving the way to a personalized medicine approach.https://www.mdpi.com/1422-0067/22/17/9454microRNAsGLP1-RAtype 2 diabetesobesitypersonalized medicine |
| spellingShingle | Caterina Formichi Daniela Fignani Laura Nigi Giuseppina Emanuela Grieco Noemi Brusco Giada Licata Claudia Sabato Elisabetta Ferretti Guido Sebastiani Francesco Dotta Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study International Journal of Molecular Sciences microRNAs GLP1-RA type 2 diabetes obesity personalized medicine |
| title | Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study |
| title_full | Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study |
| title_fullStr | Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study |
| title_full_unstemmed | Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study |
| title_short | Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study |
| title_sort | circulating micrornas signature for predicting response to glp1 ra therapy in type 2 diabetic patients a pilot study |
| topic | microRNAs GLP1-RA type 2 diabetes obesity personalized medicine |
| url | https://www.mdpi.com/1422-0067/22/17/9454 |
| work_keys_str_mv | AT caterinaformichi circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy AT danielafignani circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy AT lauranigi circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy AT giuseppinaemanuelagrieco circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy AT noemibrusco circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy AT giadalicata circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy AT claudiasabato circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy AT elisabettaferretti circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy AT guidosebastiani circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy AT francescodotta circulatingmicrornassignatureforpredictingresponsetoglp1ratherapyintype2diabeticpatientsapilotstudy |